Utility values associated with advanced or metastatic non-small cell lung cancer: data needs for economic modeling

References

• Ramsey, SD, et al. Cost–effectiveness analysis alongside clinical trials II–an ISPOR Good Research Practices Task Force report. Value Health. 2015;18(2):161–172.
   PubMed Web of Science ®Google Scholar
• National Institute for Health and Care Excellence. Guide to the methods of technology appraisal 2013. [cited 2015 October 8]; Available from: http://publications.nice.org.uk/pmg9.
   Google Scholar
• Schnipper, LE, et al. American society of clinical oncology statement: a conceptual framework to assess the value of cancer treatment options. J Clin Oncol. 2015;33(23):2563–2577.
   PubMed Web of Science ®Google Scholar
• Gold, MR, et al., Identifying and valuing outcomes, in Cost-effectiveness in health and medicine, M.R. Gold, et al. In: Editors. 1996. Oxford: Oxford University Press.
   Google Scholar
• The EuroQol Group. EuroQol–a new facility for the measurement of health-related quality of life. Health Policy. 1990;16(3):199–208.
   PubMed Web of Science ®Google Scholar
• Bennet KJ, Torrance GW. Measuring health state preferences and utilities: rating scale, time trade-off, and standard gamble techniques. In: Spilker B, Editor. Quality of life and pharmacoeconomics in clinical trials, second edition. Philadelphia: Lippincott-Raven Publishers; 1996.
   Google Scholar
• Sturza J. A review and meta-analysis of utility values for lung cancer. Med Decis Making. 2010;30(6):685–693.
   PubMed Web of Science ®Google Scholar
• De Geer A, Eriksson J, Finnern HW. A cross-country review of data collected on non-small cell lung cancer (NSCLC) patients in cancer registries, databases, retrospective and non-randomized prospective studies. J Med Econ. 2012;16(1):134–149.
   PubMedGoogle Scholar
• Chouaid, C, et al. Economic evaluation of first-line and maintenance treatments for advanced non-small cell lung cancer: a systematic review. Clinicoecon Outcomes Res. 2015;7:9–15.
   PubMed Web of Science ®Google Scholar
• Lange, A, et al. A systematic review of the cost-effectiveness of targeted therapies for metastatic non-small cell lung cancer (NSCLC). BMC Pulm Med. 2014;14:192.
   PubMed Web of Science ®Google Scholar
• Rittmeyer A. Quality of life in patients with nsclc receiving maintenance therapy. Cancers (Basel). 2015;7(2):950–962.
   PubMedGoogle Scholar
• Saad, ED, et al. Assessment of quality of life in advanced non-small-cell lung cancer: an overview of recent randomized trials. Cancer Treat Rev. 2012;38(6):807–814.
   PubMed Web of Science ®Google Scholar
• Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. Higgins J, Green S, Editors. The Cochrane Collaboration. 2011.
   Google Scholar
• Papaioannou D, Brazier J, Paisley S, NICE DSU Technical Support Document 9: the identification, review and synthesis of health state utility values from the literature. 2011: Available from http://www.nicedsu.org.uk.
   Google Scholar
• Moher, D, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med. 2009;151:264–269.
   PubMed Web of Science ®Google Scholar
• Lee, LJ-H, et al. Comparison of the quality of life between patients with non-small-cell lung cancer and healthy controls. Qual Life Res. 2011;20:415–423.
   PubMed Web of Science ®Google Scholar
• Novello, S, et al. Analysis of patient-reported outcomes from the LUME-Lung 1 trial: a randomised, double-blind, placebo-controlled, Phase III study of second-line nintedanib in patients with advanced non-small cell lung cancer. Eur J Cancer. 2015;51:317–326.
   PubMed Web of Science ®Google Scholar
• Gridelli, C, et al. Safety, resource use, and quality of life in paramount: a phase III study of maintenance pemetrexed versus placebo after induction pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer. J Thorac Oncol. 2012;7:1713–1721.
   PubMed Web of Science ®Google Scholar
• Lal, R, et al. Feasibility of home delivery of pemetrexed in patients with advanced non-squamous non-small cell lung cancer. Lung Cancer. 2015;89:154–160.
   PubMed Web of Science ®Google Scholar
• Bischoff, HG, et al. Observation of the treatment and outcomes of patients receiving chemotherapy for advanced NSCLC in Europe (ACTION study). Curr Med Res Opin. 2010;26:1461–1470.
   PubMed Web of Science ®Google Scholar
• Dooms CA, Lievens YN, Vansteenkiste JF. Cost-utility analysis of chemotherapy in symptomatic advanced nonsmall cell lung cancer. Eur Respir J. 2006;27:895–901.
   PubMed Web of Science ®Google Scholar
• Doyle S, Lloyd A, Walker M. Health state utility scores in advanced non-small cell lung cancer. Lung Cancer. 2008;62:374–380.
   PubMed Web of Science ®Google Scholar
• Galetta, D, et al. Cisplatin/Pemetrexed followed by maintenance Pemetrexed versus Carboplatin/Paclitaxel/Bevacizumab followed by maintenance bevacizumab in advanced nonsquamous lung cancer: the GOIM (Gruppo Oncologico Italia Meridionale) ERACLE Phase III Randomized Trial. Clin Lung Cancer. 2015;16:262–273.
   PubMed Web of Science ®Google Scholar
• Grutters, JPC, et al. Health-related quality of life in patients surviving non-small cell lung cancer. Thorax. 2010;65:903–907.
   PubMed Web of Science ®Google Scholar
• Iyer S, Taylor-Stokes G, Roughley A. Symptom burden and quality of life in advanced non-small cell lung cancer patients in France and Germany. Lung Cancer. 2013;81:288–293.
   PubMed Web of Science ®Google Scholar
• Khan, I, et al. Cost-effectiveness of first-line erlotinib in patients with advanced non-small-cell lung cancer unsuitable for chemotherapy. BMJ Open. 2015;5:e006733.
   PubMed Web of Science ®Google Scholar
• Lamers LM, Uyl-De Groot CA, Buijt I. The use of disease-specific outcome measures in cost-utility analysis: the development of Dutch societal preference weights for the FACT-L scale. Pharmacoeconomics. 2007;25:591–603.
   PubMed Web of Science ®Google Scholar
• Lewis G, et al. Cost-effectiveness of erlotinib versus docetaxel for second-line treatment of advanced non-small-cell lung cancer in the United Kingdom. J Int Med Res. 2010;38:9–21.
   PubMed Web of Science ®Google Scholar
• Nafees, B, et al. Health state utilities for non small cell lung cancer. Health and Qual Life Outcomes. 2008;6:84.
   PubMed Web of Science ®Google Scholar
• Roughley, A, et al. Impact of brain metastases on quality of life and estimated life expectancy in patients with advanced non-small cell lung cancer. Value Health. 2014;17:A650.
   PubMed Web of Science ®Google Scholar
• Schuette, W, et al. Second-line treatment of stage III/IV non-small-cell lung cancer (NSCLC) with pemetrexed in routine clinical practice: evaluation of performance status and health-related quality of life. BMC Cancer. 2012;12:14.
   PubMed Web of Science ®Google Scholar
• Trippoli, S, et al. Quality of life and utility in patients with non-small cell lung cancer. Quality-of-life study group of the master 2 project in pharmacoeconomics. Pharmacoeconomics. 2001;19:855–863.
   PubMed Web of Science ®Google Scholar
• Van Den Hout WB, et al. Cost-utility analysis of short- versus long-course palliative radiotherapy in patients with non-small-cell lung cancer. J Natl Cancer Inst. 2006;98:1786–1794.
   PubMedGoogle Scholar
• Verduyn, SC, et al. Estimating quality adjusted progression free survival of first-line treatments for EGFR mutation positive non small cell lung cancer patients in The Netherlands. Health and Qual Life Outcomes. 2012;10:108.
   PubMed Web of Science ®Google Scholar
• Berthelot, JM, et al. Decision framework for chemotherapeutic interventions for metastatic non-small-cell lung cancer. J Natl Cancer Inst. 2000;92:1321–1329.
   PubMed Web of Science ®Google Scholar
• Blackhall, F, et al. Patient-reported outcomes and quality of life in PROFILE 1007: a randomized trial of crizotinib compared with chemotherapy in previously treated patients with ALK-positive advanced non-small-cell lung cancer. J Thorac Oncol. 2014;9:1625–1633.
   PubMed Web of Science ®Google Scholar
• Chouaid, C, et al. Health-related quality of life and utility in patients with advanced non-small-cell lung cancer: a prospective cross-sectional patient survey in a real-world setting. J Thorac Oncol. 2013;8:997–1003.
   PubMed Web of Science ®Google Scholar
• Hirsh, V, et al. Symptom and quality of life benefit of afatinib in advanced non-small-cell lung cancer patients previously treated with erlotinib or gefitinib: results of a randomized phase IIb/III trial (LUX-Lung 1). J Thorac Oncol. 2013;8:229–237.
   PubMed Web of Science ®Google Scholar
• Horgan, AM, et al. An economic analysis of the INTEREST trial, a randomized trial of docetaxel versus gefitinib as second-/third-line therapy in advanced non-small-cell lung cancer. Ann Oncology. 2011;22:1805–1811.
   PubMed Web of Science ®Google Scholar
• Jang, RW, et al. Derivation of utility values from European Organization for research and treatment of cancer quality of life-core 30 questionnaire values in lung cancer. J Thorac Oncol. 2010;5:1953–1957.
   PubMed Web of Science ®Google Scholar
• Manser, RL, et al. Validity of the assessment of quality of life (AQoL) utility instrument in patients with operable and inoperable lung cancer. Lung Cancer. 2006;53:217–229.
   PubMed Web of Science ®Google Scholar
• Yang, S-C, et al. Estimation of loss of quality-adjusted life expectancy (QALE) for patients with operable versus inoperable lung cancer: adjusting quality-of-life and lead-time bias for utility of surgery. Lung Cancer. 2014;86:96–101.
   PubMed Web of Science ®Google Scholar
• Kind P, Macran S. Eliciting social preference weights for Functional Assessment of Cancer Therapy-Lung health states. Pharmacoeconomics. 2005;23:1143–1153.
   PubMed Web of Science ®Google Scholar
• Dolan P. Modeling valuations for EuroQol health states. Med Care. 1997;35(11):1095–1108.
   PubMed Web of Science ®Google Scholar
• Hirsch, FR, et al. The prognostic and predictive role of histology in advanced non-small cell lung cancer: a literature review. J Thorac Oncol. 2008;3(12):1468–1481.
   PubMed Web of Science ®Google Scholar
• Oliver TG, Patel J, Akerley W. Squamous non-small cell lung cancer as a distinct clinical entity. Am J Clin Oncol. 2015;38(2):220–226.
   PubMed Web of Science ®Google Scholar
• Tabberer M, et al. PCN74 utilities associated with non-small cell lung cancer (NSCLC): A community study. Value Health. 2006;9(6):A298
   Google Scholar